Local Institution

Gdansk 80952

0 studies enrolling now · 29 studies all time

What they study most

Acute Coronary Syndrome (ACS), Advanced Non-small Cell Lung Cancer, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-small Cell Lung, Deep Vein Thrombosis, Gastric/Esophageal Adenocarcinoma, Hepato Cellular Carcinoma (HCC), Hodgkin Disease, Leukemia

Studies at this site

• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients — Completed
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment — Completed
• Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation — Stopped early
• A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer — Completed
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) — Completed
• Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes — Completed
• Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) — Stopped early
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker — Completed
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer — Stopped early
• Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types — Completed
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma — Completed
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML — Completed
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) — Completed
• Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer — Completed
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery — Completed